Annovis Bio Inc Total Assets
Annovis Bio Inc total assets. Based on the latest financial reports, Annovis Bio Inc (ANVS) holds total assets worth $16.24 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Annovis Bio Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Annovis Bio Inc (2009–2025)
Total assets of Annovis Bio Inc from 2009 to 2025. This chart illustrates how Annovis Bio Inc's total assets have evolved over time, based on quarterly financial data. See ANVS live share price for real-time trading data and today's change.
Annovis Bio Inc - Asset Composition Analysis
Annovis Bio Inc Total Assets Breakdown (December 2025)
Annovis Bio Inc total assets breakdown as of December 2025. Annovis Bio Inc's total assets of $16.24 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Annovis Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Annovis Bio Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Annovis Bio Inc's current assets represent 100.0% of total assets in 2025, an increase from 8.0% in 2009.
- Cash Position: Cash and equivalents constituted 92.7% of total assets in 2025, up from 2.1% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 90.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Annovis Bio Inc Competitors by Total Assets
Key competitors of Annovis Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Annovis Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 10.68 | 55.99 |
| Quick Ratio | 1.27 | 10.68 | 55.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.45 Million | $24.23 Million | $48.61 Million |
Annovis Bio Inc - Advanced Valuation Insights
This section examines the relationship between Annovis Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 25.58 |
| Latest Market Cap to Assets Ratio | 1.70 |
| Asset Growth Rate (YoY) | 51.4% |
| Total Assets | $21.08 Million |
| Market Capitalization | $35.94 Million USD |
Valuation Analysis
Above Book Valuation: The market values Annovis Bio Inc's assets above their book value (1.70x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Annovis Bio Inc's assets grew by 51.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Annovis Bio Inc (2009–2025)
The table below shows the annual total assets of Annovis Bio Inc from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $21.08 Million | +51.39% |
| 2024-12-31 | $13.93 Million | +36.42% |
| 2023-12-31 | $10.21 Million | -71.66% |
| 2022-12-31 | $36.02 Million | -21.69% |
| 2021-12-31 | $46.00 Million | +466.57% |
| 2020-12-31 | $8.12 Million | +626.82% |
| 2019-12-31 | $1.12 Million | +2090.75% |
| 2018-12-31 | $50.99K | -85.75% |
| 2017-12-31 | $357.96K | -87.37% |
| 2012-12-31 | $2.84 Million | -86.51% |
| 2011-12-31 | $21.01 Million | -4.68% |
| 2010-12-31 | $22.05 Million | +1348.62% |
| 2009-12-31 | $1.52 Million | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more